 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 1 of 41 
 
Neurolief  Confidential  
  
  
 
Neurolief  
Abridged Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  The RIME study - Combined occipi[INVESTIGATOR_288311]-302-RIME  
Study Product Name  [CONTACT_132655]â„¢  
Sponsor  Neurolief  Ltd. 
12 Giborei Israel  
Netanya, 4250412 Israel  
Phone: [PHONE_2959]  
Contact: [CONTACT_288352]  
e-mail: michal.kedar -[EMAIL_5646]     
 
Document Version  Rev. 2 / June 11 , 2019 (Abridged)  
 
Confidentiality Statement  
The information  contained  in this document  is confidential  and the proprietary  property  of Neurolief . 
Any distribution,  copying,  or disclosure  without  the prior  written  authorization  of Neurolief  is strictly  
prohibited.  Persons  to whom  the information  is disclosed  must  know  that it is confidential  and that it 
may  not be further  disclosed  by [CONTACT_476].  
 
 
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351389] Description ................................ ................................ ................................ ..........  16 
5.1. General  ................................ ................................ ................................ ................................ . 16 
5.2. Mode of Action ................................ ................................ ................................ .......................  17 
5.3. Dosage Form  ................................ ................................ ................................ .........................  18 
5.4. Intended Use & Intended Population  ................................ ................................ .......................  [ADDRESS_351390] Enrollment  ................................ ................................ ................................ .................  20 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 3 of 41 
 
Neurolief  Confidential  
  
  
7.3. Inclusion Criteria  ................................ ................................ ................................ ....................  21 
7.4. Exclusion Criteria  ................................ ................................ ................................ ...................  21 
8. Study P rocedures  ................................ ................................ ................................ .............  22 
8.1. Schedule of Events  ................................ ................................ ................................ .................  22 
8.1.1.  Visit 1 - Run-in (day -28) ................................ ................................ ................................ ........  24 
8.1.2.  Run-In Period (Day 0 -28+10 days)  ................................ ................................ ........................  24 
8.1.3.  Visit 2 - Randomization (28+10 days from Visit 1)  ................................ ................................  24 
8.1.4.  Self-Practice Period (up to 14 days)  ................................ ................................ ......................  25 
8.1.5.  Visit 3 (remotely or clinic visit; up to day 14) ................................ ................................ ........  25 
8.1.6.  Treatment period (up to 5 treated Migraine epi[INVESTIGATOR_288312] 70+[ADDRESS_351391])
 26 
8.1.7.  Visit 4 - Termination visit (following 5 treated Migraine epi[INVESTIGATOR_288312] 70+10, whichever 
comes first)  ................................ ................................ ................................ ................................ .........  [ADDRESS_351392] Consent  ................................ ................................ ................................ .....................  28 
8.4. Randomization, Treatment Assignment and Blinding  ................................ ................................  28 
8.5. Medication Compliance  ................................ ................................ ................................ ...........  28 
8.6. Assessment of Efficacy  ................................ ................................ ................................ ...........  29 
8.7. Assessment of Safety  ................................ ................................ ................................ .............  29 
9. Risks and Benefits  ................................ ................................ ................................ ............  29 
9.1. Risk Co ntrol and Mitigation  ................................ ................................ ................................ ..... 29 
9.2. Risk-Benefit Rationale  ................................ ................................ ................................ ............  29 
10. Adverse Events and Device Deficiencies  ................................ ................................ ....... 30 
10.1.  Relivion Anticipated Adverse Events  ................................ ................................ ..................  30 
10.1.1.  Reporting of Adverse Events  ................................ ................................ .............................  30 
10.1.2.  Safety Monitoring and Adjudication of Adverse Events  ................................ ....................  31 
11. Statistical Considerations  ................................ ................................ ..............................  32 
11.1.  Study Endpoint Variables  ................................ ................................ ................................ .. 32 
11.1.1.  Primary endpoint variable  ................................ ................................ ................................ . 32 
11.1.2.  Secondary endpoint variables  ................................ ................................ ...........................  32 
11.1.3.  Exploratory endpoint variables  ................................ ................................ .........................  32 
11.1.4.  Safety endpoint variables  ................................ ................................ ................................ .. 32 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 4 of 41 
 
Neurolief  Confidential  
  
  
11.2.  Study Hypothesis  ................................ ................................ ................................ .............  32 
11.3.  Samp le Size Estimation  ................................ ................................ ................................ ..... 33 
11.4.  Interim Analysis  ................................ ................................ ................................ ...............  33 
11.4.1.  Procedure  ................................ ................................ ................................ ..........................  34 
11.4.2.  Blinding  ................................ ................................ ................................ ..............................  34 
11.4.3.  Decision Rules  ................................ ................................ ................................ ....................  34 
11.4.4.  Controlling the Alpha Level for the Primary Endpoint  ................................ ......................  35 
11.5.  Randomization  ................................ ................................ ................................ .................  35 
11.6.  Analysis Populations  ................................ ................................ ................................ .........  35 
11.7.  Statistical Analysis  ................................ ................................ ................................ ............  36 
11.7.1.  General Considerations  ................................ ................................ ................................ ..... 36 
11.7.2.  Significance Level and Handling of Type I Error  ................................ ................................  36 
11.7.3.  Demographic and Other Baseline Chara cteristics  ................................ .............................  36 
11.7.4.  Disposition of Subjects  ................................ ................................ ................................ ...... 37 
11.7.5.  Efficacy Analysis  ................................ ................................ ................................ .................  37 
12. References  ................................ ................................ ................................ .....................  40 
 
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351393] Bothersome migraine -related Symptom  
mITT  modified Intent to Treat  
NSR Non -Significant Risk  
ONS  Occipi[INVESTIGATOR_288313]-TNS Occipi[INVESTIGATOR_288314]  
P/N Part Number  
PNS Peripheral Nerve Stimulation  
PRO  Patient Reported Outcome  
RA Return Authorization  
RDC Remote Data Capture  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
TENS  Transcutaneous Electrical Nerve Stimulation  
UM User Manual  
US [LOCATION_002]  
U(S)ADE  Unanticipated (Serious) Adverse Device Effect  
VAS Visual Analog Scale  
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 6 of 41 
 
Neurolief  Confidential  
  
  
2. Synopsis  
Title  The RIME study - Combined occipi[INVESTIGATOR_288315], Non -Significant Risk (NSR) Device Study  
Product Name  [CONTACT_132655] â„¢ (Device version RLV3; SW version 0.3.21 ; App Version 1. 0) 
Sponsor  Neurolief  Ltd. 
US Agent  Elaine J. Whitmore, Ph.D.  
SciVance Consulting  
[ADDRESS_351394].  
Bradenton, [LOCATION_012] [ZIP_CODE]  
Indication under 
investigation  The Relivionâ„¢  is a non -invasive transcutaneous neuro -stimulator 
intended for treatment of headache and is indicated for the acute 
treatment of migraine with or without aura in subjects 18 years of age 
or older.  The Relivion is intended to be a prescription device, sel f-used 
at home.  
Investigation Purpose  The RIME Study will evaluate the safety and efficacy   of a self -
administered abortive treatment for migraine headache using 
combined occipi[INVESTIGATOR_288316] 
(Relivionâ„¢).  
 
This pi[INVESTIGATOR_288317]â€™s Relivion device in the context of its initial FDA 
clearance under [ADDRESS_351395] -
treatment, without rescue medications, when using active combined 
occipi[INVESTIGATOR_288318] 
(Relivion â„¢) compared to sham stimulation, in subjects suffering f rom 
acute migraine headache. Pain score will be assessed on a 4 -point scale 
whereas 0 =no pain, 1=Mild pain, 2=Moderate pain, 3= Severe pain  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351396] bothersome migraine -associated symptom (MBS) 
other than a headache, without rescue medications, 2 hours from 
Relivionâ„¢ treatment initiation compared to sham stimulation, in 
subjects s uffering from acute migraine headache. MBS may be 
nausea, photophobia or phonophobia .  
2. To assess the proportion of subjects reporting headache relief at 
1-hour  without rescue med ication s, compared to sham 
stimulation .   
3. To assess the proportion of subjects  who are pain free at 2 hours 
from Relivionâ„¢ treatment initiation without rescue medications, 
compared to sham stimulation, in subjects suffering from acute 
migraine headache.  
Safety Objective  To demonstrate safety in using the Relivionâ„¢ device . 
Exploratory Objectives  1. To assess the proportion of subjects reporting freedom from their 
MBS other than a headache, without rescue medications, 2 hours 
from Relivionâ„¢ treatment initiation compared to sham 
stimulation, in subjects suffering from acute migra ine headache.  
2. To assess the p roportion of subjects who are pain free at [ADDRESS_351397] Relivionâ„¢ treatment initiation (if rescue therapy was not 
used), in their first treated migraine attack.  
3. To assess the subjects positive Global Impression of Effect of 
stud y device at the end of the study, defined as satisfied or very 
satisfied using a simple Likert -type scale whereas 1 = Very 
dissatisfied, 2 = dissatisfied, 3 = unsure, 4 = satisfied, 5 = Very 
satisfied, in active versus sham stimulation . 
4. To assess the propo rtion of subjects reporting headache relief 
without taking  rescue medications within 2 and 24 hours from 
Relivionâ„¢ treatment initiation compared to sham stimulation, in 
subjects suffering from acute migraine headache.  
Planned Study Duration  Each subject will participate in the study for up to 110 days (~16 
weeks) including the run -in period. The overall enrollment period is 
expected to last approximately 12 months.  
Study Design  Multi -center, p rospective, 2 -arms randomized, double -blind, parallel -
group, sham controlled study . The study will include the following 
study periods : 
â€¢ Run-in Period  (28+10 days)  
â€¢ Randomization  to Relivionâ„¢  vs. Sham control ( 1:1 randomization) 
and Self-Practice Period  (up to 14 days)  
â€¢ Treatment Period  (up to 5 migraine attacks or 70 +[ADDRESS_351398])  
 
After completion of the Treatment Period  the subjectâ€™s participation 
will be over.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 8 of 41 
 
Neurolief  Confidential  
  
  
The study will be conducted at a maximum of 12 investigational sites 
in the U nited States (U S) and Israel ,; Sites in the US will enroll 
approximately 33% of total subjects. Each site will enroll a maximum 
of 60 subjects.  
Randomization  Upon completion of the run -in period, eligible subjects will be 
randomly allocated (with a 1:1 ratio) to one of the following 2 
treatment groups based on a randomization scheme using the 
permuted block method stratified by [CONTACT_384]:  
â€¢ Group A - active stimulation  
â€¢ Group B - sham stimulation  
The randomization scheme will be prepared by [CONTACT_288353] (version 9.4.) random number procedure. The block size 
will be random, and all study personnel will be therefore blinded to the 
randomi zation block size.  
Sample Size  The planned sample size is up to 200 randomized subjects, to allow for 
90 evaluable subjects per treatment group, anticipating 10% drop -
out.    
One interim analysis is planned after 144 (80%) evaluable subjects 
have been accr ued.  
Inclusion Criteria  1. Subjects [ADDRESS_351399] meets the ICHD -3 (2018) diagnostic criteria for Migraine  
with or without aura .  
3. Subject reports 1-6 Migraine attacks per month; other headaches 
no more than [ADDRESS_351400] 6 months  of chronic migraine, New Daily Persistent 
Headache, and chronic tension -type headache per ICHD -3 (2018) 
diagnostic criteria . 
4. Current medication overuse headache . 
5. Use of opi[INVESTIGATOR_288319] 1 month . 
6. Use of barbiturates in the prior 1 month . 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351401] has >10 headache days per month  
8. Implanted metal/shrapnel or electrical devices in the head (not 
including dental implants), a cardiac pacemaker or an implanted 
or wearable defibrillator.  
9. Received parenteral infusions for migraine within the previous [ADDRESS_351402] with implanted neurostimulators, surgical clips (above the 
shoulder line) or any medical pumps.  
13. Current drug abuse or alcoholism.  
14. Subject is participating in any other clinical study . 
15. Skin lesion o r inflammation at the region of the stimulating 
electrodes.  
16. Personality or somatoform disorder.  
17. Pregnancy or Lactation.  
18. Women  with child bearing potential without medically acceptable 
method of contraception (NOTE: Females of child bearing 
potential must h ave a negative pregnancy test) . 
19. Documented history of cerebrovascular event.  
20. Subject with recent brain or facial trauma (occurred less than 3 
months prior to this study).  
21. Subject participated in a previous study with the Relivion device . 
22. The subject does n ot have the basic cognitive and motor skills 
needed to operate a smartphone.  
23. Subject with head circumference smaller than [ADDRESS_351403] eligible (per section 
9.1.6) treated migraine attack, when using active combined occipi[INVESTIGATOR_288320], in subjects suffering from acute migraine headache.  
Use of rescue medicat ion prior to [ADDRESS_351404]  treatment initiation  
will be considered a failure for this end -point (i.e. patient will be 
assigned the status of no reduction).  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351405] -treatment initiation (if rescue 
therapy was not used), in their first eligible treated migraine 
attack.  MBS may be nausea, photophobia, phonophobia as 
defined by [CONTACT_288354].  
2. Proportion of  subjects reporting reduction of migraine headache 
pain [ADDRESS_351406] treatment initiation (if rescue therapy was not 
used), from severe or moderate to mild or no pain, or from mild 
to no pain, in their first eligible treated migraine attack.  
3. Proportion of s ubjects who are pain free at [ADDRESS_351407] 
treatment initiation (if rescue therapy was not used), in their first 
eligible treated migraine attack.   
Safety Endpoint  Safety of the study device following study treatment: Rate of Adverse 
events related or unrelated to the study device [ Time Frame: [ADDRESS_351408] treatment initiation].  
Exploratory Endpoints  1. Proportion of subjects reporting freedom from their MBS other 
than a headache, [ADDRESS_351409] -treatment initiation (if rescue 
therapy was not used), in their first eligible treated migraine attack.  
2. Proportion of subjects who are pain free at [ADDRESS_351410] treatment 
initiation (if rescue therapy was not used), in their first eligible 
treated migraine attack.  
3. Proportion of subjects rating the subjects positiv e (score of 4 or 5) 
Global Impression of Effect of study device at the end of the study, 
defined as satisfied or very satisfied using a simple Likert -type scale 
whereas 1 = Very dissatisfied, 2 = dissatisfied, 3 = unsure, 4 = 
satisfied, 5 = Very satisfied.  
4. Proportion of subjects reporting [ADDRESS_351411] e ligible 
treated migraine attack .  
 Statistic al Considerations  Study Hypothesis:  
H0: PT = P S 
HA: PT â‰  P S 
Where P T and P S represent the proportion (%) of subjects reporting 
pain relief in the active treatment group and sham group respectively   
Sample Size Estimation:  
The sample size for this study was calculated to test the null 
hypothesis with a chi -squared test, even though the final analysis may 
employ a regression model and/or a Fisherâ€™s exact test.  
Sample sizes are calculated to test the null hypothesis with 80% 
power at a 5% level of significance.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 11 of 41 
 
Neurolief  Confidential  
  
  
If we assume that 45% of the subjects in the active treatment arm will 
have successful pain relief versus 25% in the sham arm, 180 evaluable 
subjects are required, 90 per group. Allowing for a ~10% drop -out 
rate, a total of 200 (100 active vs. 100 sham) subjects should be 
enrolled in the study.    
Interim Analysis:   
One interim analysis is planned after 144 (80%) e valuable subjects 
have been accrued . The study will then either continue to the 
originally planned sample size if the result is â€œfavorableâ€, stop for 
futility if the result is â€œunfavorableâ€, or an increase  will be made to  
the sample size if the result is â€œpromisingâ€ these decisions will be 
made based on the cond itional power (CP), defined as the conditional 
probability that the final result will exceed a critical value at the 
interim given the observed effect size  ð›¿1Ì‚ = difference between pain 
reduction rates in the active versus control groups at the interim lo ok. 
Primary endpoint analysis:  
The primary endpoint is the p roportion  of subjects reporting  
reduction of migraine headache  pain  [ADDRESS_351412] treated migraine attack, when using active combined 
occipi[INVESTIGATOR_288321], in subjects suffering from acute 
migraine headache . Use of r escue medication will be considered  a 
failure for this end -point (i.e. patient will be assigned the status of no 
reduction) .  
A count and percentage of subjects reporting such headache pain 
reduction without rescue medications  will be calculated and 
presented for both study groups, each with a two -sided 95% exact 
confidence interval. The groups will be compared with a chi -squared 
test and a Fisherâ€™s exact test.  
If the null hypothesis is rejected in favor of the alternative hyp othesis 
and the proportion (%) of subjects reporting  reduction of migraine in 
the treated group is greater than that of the sham group, the study 
will be deemed successful.  
 
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 12 of 41 
 
Neurolief  Confidential  
  
  
3. Introduction  
3.1. Background  
Migraine is a prevalent and debilitating primary headache disorder. In the U.S population the prevalence 
of migraine is approximately 18% in women and 6% in men  [1].  The World Health Organization (WHO) 
estimates that half to three quarters of adults aged [ADDRESS_351413] year and, among those individuals, 30% or more have reported migraine  [2]. Migraine prevalence is 
highest in those aged 30 to 39 years  [3]. Migraine patients suffer from disabling symptoms that usually 
consist of a moderate to severe headache  lasting 4 to 72 hours, nausea and/or vomiting, phonophobia 
(noise  sensitivity ) and photophobia (light  sensitivity ). Seventy five percent ( 75% ) have a reduced ability 
to function during the migraine epi[INVESTIGATOR_49591] 33% require bed rest during their attacks  [3]. Patients with 
migraine are often refractory to medical treatment and some of the most effective anti -migraine drugs , 
such as Triptans , have substantial side effects [ 4]. 
Triptans are the first -line therapy for patients whose attacks do not reliably respond to simple or 
combination analgesics  [4]. The Most common side effects of Triptans are dizziness, nausea, weakness, 
tiredness, drowsiness, p aresthesias, flushing, neck tightness and chest pressure which occur in about 
20% of patients. Triptans have also been associated with the development of headache caused by 
[CONTACT_160459]. Therefore, most experts recommend a conservative limit on its u se to about 2 days 
per week  [2]. Serious cardiovascular events, some resulting in death, have been reported in association 
with the use of Triptans. Thus, Triptans are contraindicated in an estimated 4.7 million Americans with 
migraine  [4]. These contraind ications and side effects have left millions of patients without a proper 
solution for their pain. Therefore, these patients may benefit from other, non -pharmaceutical strategies 
to modulate their pain. One of the tools to achieve pain reduction is Periphe ral Nerve Stimulation (PNS). 
PNS can be applied either invasively or non -invasively. Invasive PNS involves surgery that places a small 
electrical device next to one of the peripheral nerves. Invasive procedures of PNS for treatment of 
migraine include  occipi[INVESTIGATOR_288322] (ONS) which has been  shown to provide relief for chronic 
migraine in numerous clinical trials  [5-9]. Another more recent PNS procedure for treatment of migraine 
combines both occipi[INVESTIGATOR_288323]  [10,11] . Recent clinical studies support the 
expectation that applying peripheral nerve stimulation to a combination of the occipi[INVESTIGATOR_288324] a better outcome compared to stimulation of the occipi[INVESTIGATOR_288325]  [10,11] . 
Indeed, the respo nse rate for patients with intractable head -wide pain who were treated with implanted 
PNS to the occipi[INVESTIGATOR_288326] 90%  [10,11] .  This is an 
improvement from using stimulation to the occipi[INVESTIGATOR_288327] i s reported to bring about just a 
40% response rate  [10]. However, implanted peripheral nerve stimulation remains an invasive and costly 
procedure with high rate of complications including infection, bleeding or fluid collection under the skin, 
as well as h ardware -related malfunctions such as migration and breakage of the implanted leads and 
pulse generator failure  [5]. Thus, these procedures are currently offered only for intractable severe 
cases of chronic migraine.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 13 of 41 
 
Neurolief  Confidential  
  
  
Transcutaneous nerve stimulation is a n oninvasive technique that for decades was considered of 
potential benefit for patients with headache  [12]. Supraorbital transcutaneous stimulation has been 
applied and found to be safe and effective as a prophylactic therapy for migraine. In a sham -control led 
trial, therapeutic gain was found to be within the range of those reported for other preventive drug and 
non-drug antimigraine treatments  [13]. In a safety and patientsâ€™ satisfaction survey of 2,313 patients 
using transcutaneous supraorbital stimulatio n, no serious adverse events were reported  [14]. In a recent 
trial [15] of supraorbital stimulation for acute treatment of migraine, a significant difference was shown 
in pain reduction between the sham and active treatment, with no significant adverse eve nts.  
Due to the challenge of transferring current through the hair, stimulation of the occipi[INVESTIGATOR_132472] [ 5,6,8,16 ] and percutaneous [ 17] nerve stimulators. However , due to its 
superficial anatomic location at the level of  the external occipi[INVESTIGATOR_132473] [ 18, 19] once the 
electrodes are placed under the hair and close enough to the scalp, it can be stimulated 
transcutaneously .  It may  thereby [CONTACT_288355].  A combined occipi[INVESTIGATOR_288328] a safe, effective and fast acting treatment for r educing migraine related 
pain.  
According to this rationale, Neurolief is developi[INVESTIGATOR_288329]â„¢ - a transcutaneous neuro -stimulator 
applying combined occipi[INVESTIGATOR_288330] . Following complet ion of early clinical studies showing favorable results, Neurolief designed 
the proposed clinical trial to evaluate the safety and efficacy of the R elivion â„¢ in a two -arms controlled, 
double blinded randomized study.  
3.2. Purpose  
The RIME Study will evaluate the  safety and efficacy   of a self -administered abortive treatment for 
migraine headache using combined occipi[INVESTIGATOR_288316] 
(Relivionâ„¢).  
This pi[INVESTIGATOR_288331]â€™s Relivionâ„¢ 
device in the context of its initial FDA clearance under 21 CFR part 882.5891, Transcutaneous electrical 
nerve stimulator to treat headache.   
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351414] -treatment, without rescue medications, 
when using active combined occipi[INVESTIGATOR_288318] (Relivion â„¢) 
compared to sham stimulation, in subjects suffering from acute migraine headache. Pain s core will be 
assessed on a 4 -point scale whereas 0 =no pain, 1=Mild pain, 2=Moderate pain, 3= Severe pain  
4.1.2.  Secondary Objectives  
1. To assess the proportion of subjects reporting improvement in their most bothersome migraine -
associated symptom (MBS) other than  a headache, without rescue medications, 2 hours from 
Relivionâ„¢ treatment initiation compared to sham stimulation, in subjects suffering from acute 
migraine headache.  MBS may be nausea, photophobia or phonophobia . 
2. To assess the proportion of subjects reporting headache relief at 1-hour  without rescue 
med ication s, compared to sham stimulation.    
3. To assess the proportion of subjects who are pain free at 2 hours from Relivionâ„¢ treatment 
initiation without rescue medications, compared to sham stimulation, in subjects suffering from 
acute migraine headache.  
4.1.3.  Safety  Objective  
To demonstrate safety in using the Relivionâ„¢ device . 
4.1.4.  Exploratory Objectives  
1. To assess the proportion of subjects reporting freedom from their MBS other than a headache, 
without rescue medications, 2 hours from Relivionâ„¢ treatment initiation compared to sham 
stimulation, in subjects suffering from acute migraine headache.  
2. To assess the p roportion of subjects who are pain free at [ADDRESS_351415] Relivionâ„¢ treatment initiation 
(if rescu e therapy was not used), in their first treated migraine attack.  
3. To assess the subjects positive Global Impression of Effect of study device at the end of the study, 
defined as satisfied or very satisfied using a simple Likert -type scale whereas 1 = Very d issatisfied, 2 
= dissatisfied, 3 = unsure, 4 = satisfied, 5 = Very satisfied, in active versus sham stimulation . 
4. To assess the proportion of subjects reporting headache relief without taking  rescue medications 
within 2 and 24 hours from Relivionâ„¢ treatment  initiation compared to sham stimulation, in 
subjects suffering from acute migraine headache.  
 
 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351416] eligible treated 
migraine attack, when using active combined occipi[INVESTIGATOR_288332], in subjects suffering from acute migraine headache . 
Use of r escue medication will be considered  a failure for this end -point ( i.e. patient will be assigned the 
status of no reduction) . 
4.2.2.  Secondary Efficacy Endpoints  
1. Proportion of subjects  reporting improvement  in their MBS other than a head ache, [ADDRESS_351417] -
treatment initiation (if rescue therapy was not used) , in their first eligible treated migraine attack.  
MBS may be nausea, photophobia, phonophobia as defined by [CONTACT_288356] . 
2. Proportion of subjects r eporting reduction of migraine headache pain [ADDRESS_351418] treatment 
initiation (if rescue therapy was not used), from severe or moderate to mild or no pain, or from mild 
to no pain, in their first eligible treated migraine attack .  
3. Proportion of subjects wh o are pain free at [ADDRESS_351419] treatment initiation (if rescue therapy was 
not used), in their first eligible treated migraine attack.   
4.2.3.  Safety Endpoint  
Safety of the study device following study treatment: Rate of Adverse events related or unrelated to the 
study device [  Time  Frame:  [ADDRESS_351420] treatment initiation ]. 
4.2.4.  Exploratory Endpoints  
1. Proportion of subjects  reporting  freedom from their MBS other than a headache, [ADDRESS_351421] -
treatment initiation (if rescue therapy was not used) , in the ir first eligible treated migraine attack.  
2. Proportion of subjects who are pain free at 1-hour post treatment initiation (if rescue therapy was 
not used), in their first eligible treated migraine attack.  
3. Proportion of subjects rating the subjects positive (score of 4 or 5) Global Impression of Effect of 
study device at the end of the study, defined as satisfied or very satisfied using a simple Likert -type 
scale whereas 1 = Very dissatisfied, 2 = dissatisfied, 3 = unsure, 4 = satisfied, 5 = Very sat isfied.  
4. Proportion of subjects reporting 2-24h headache relief, defined as headache relief at 2 hours 
without rescue med ications , then no moderate to severe headache in the next 22 hours, and no use 
of rescue medication or additional stimulation . 
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351422]  Description  
5.1. General  
The Relivionâ„¢ is an external neurostimulator designed for transcutaneous electrical nerve  stimulation. 
The headset integrates three pairs of output electrodes which come in contact [CONTACT_288357] (two pairs) and  occiput (1 pair). The electrodes deliver the stimulation  pulses produced by 
[CONTACT_132553]â€™s scalp. The frontal electrodes stimulate the  trigeminal (supraorbital 
& supratrochlear) nerve branches and the posterior electrodes stimulate the  occipi[INVESTIGATOR_132480] 
(Figures 1 and 2 below). Stimulation intensity can be adjusted by [CONTACT_28024].  
The Relivionâ„¢ is a prescription device that will be self -used in a home environment.  
 
Figure 1: Relivionâ„¢ and its target nerves  
 
Figure 2: Relivionâ„¢ on a user  
 
 
The device is comprised of a headset with integrated electrodes, designed to enable stimulation of  the 
target nerves.  The on -board stimulation circuit is adapted to deliver stimulatio n patterns to  enhance 
proper nerve activation.  The headset adjusts to various head sizes and contours and can  be worn 

 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 17 of 41 
 
Neurolief  Confidential  
  
  
comfortably.  Each time the headset is worn, the six electrodes are placed over the  underlying nerves.  
Four anterior forehead electrodes  are aligned with branches of the trigeminal  nerve (supraorbital & 
supratrochlear) and two posterior electrodes are aligned with the greater  occipi[INVESTIGATOR_132480].  The 
headset includes two flexible arms that penetrate under the hair  layers while the he adset is donned.  A 
size adjustment mechanism is located at both sides of the  headset.  It enables adjustment of the 
headset size to the head of the user before first use.  The Relivionâ„¢ includes six replaceable electrode 
pads that are positioned above the  headset electrodes.   The pads consist of a water absorbing foam and 
should be wetted by [CONTACT_288358].  Water releasing covers  are located on the outer side of each oc cipi[INVESTIGATOR_288333].  After positioning the headset on the head,  the user press once on the water release covers 
to release moisture from the electrode pads onto  the scalp, thereby [CONTACT_288359].   The Relivionâ„¢ incorporates an on -board interface that enables the user to 
activate/deactivate the  device and to adjust the stimulation intensity.  It also provides visual and 
auditory indications such as  whether the device is active/non -active and when there i s a low battery.    
The Relivionâ„¢ can communicate via a low energy Bluetooth link with a mobile application on the  userâ€™s 
smartphone.  The mobile application displays the device status and provides  indications and alerts such 
as treatment intensity level, t reatment duration, low battery, charging  state, etc.  The mobile 
application is optional as the Relivionâ„¢ can be fully operated without it.   Furthermore, the device cannot 
be controlled (activate, adjust intensity, etc.) by [CONTACT_288360].  
Further details, images and specifications are provided in the User Manual.  
5.2. Mode of Action  
As explained, the Relivionâ„¢ is an external neurostimulator designed for transcutaneous electrical nerve 
stimulation. The headset integrates three pairs of output electrodes  which come in contact [CONTACT_288361].  The electrodes deliver the stimulation pulses produced by [CONTACT_288362]â€™s scalp.  The frontal electrodes stimulate the trigeminal (supraorbital and 
supratrochl ear) nerve branches and the posterior electrodes stimulate the greater occipi[INVESTIGATOR_288334].  
Overactive pain and symptom areas of the brain are believed to play a primary role in the onset of 
migraines  [20]. The Relivionâ„¢ device treats migraine by [CONTACT_288363][INVESTIGATOR_288334], thereby [CONTACT_288364] -and-symptom areas and altering the activity in pain -
associated central structures.  
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 18 of 41 
 
Neurolief  Confidential  
  
  
5.3. Dosage Form  
For purposes of this study, the Relivionâ„¢ will be provided in therapeutic and non -therapeutic modes, to 
accommodate for the Active and Sham groups:  
â€¢ Group A â€“ Active Treatment: For the therapeutic mode the device will be preset to the following 
parameters: stimulation waveform - symmetrical biphasic, phase duration 330 -400 microseconds, 
pulse frequency 80Hz, trigeminal stimulation intensity â€“ up to 6mA, Occipi[INVESTIGATOR_132484] â€“ 
up to 12mA.  
â€¢ Group B â€“ Sham Control: For the non -therapeutic mode the device will be preset to the following 
parameters: Stimulation wav eform - symmetrical biphasic, phase duration - 70-[ADDRESS_351423] 60 Â±[ADDRESS_351424] may stop treatmen t earlier.  
5.4. Intended Use & Intended Population  
The Relivionâ„¢ transcutaneous electrical nerve stimulator is intended for the treatment of headache and 
is indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older.  
It is a prescription device to be self -used at home.  
6. Study Design  
6.1. General  
Multi -center, p rospective, 2 -arms  randomized , double -blind , parallel -group, sham controlled  study  
evaluating the safety and efficacy of the of the Relivionâ„¢  in subjects 18 years of age and older  suffering 
from migraine headache with and without aura .  The study will include the following period s:  
1. Run-in Period  (28 days)  
2. Randomization to Active Relivion  vs. Sham control treatment arm (1:1 randomization) and Self-
Practice Period  (Up to 14 days)  
3. Treatment Period  (up to 5 migraine attacks or 70 +[ADDRESS_351425])  
 
After completion of the Treatment Period  the subjectâ€™s participation will be over.   
Study flow chart  is summarized in Figure 4 and details of the assessments to be completed at each 
period  / visit are provided is Section 9.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 19 of 41 
 
Neurolief  Confidential  
  
  
The planned number of subjects is 200.  There are no procedures for the replacement of subjects.  
The study will be conducted at a maximum of 12 investigational sites in the US and Israel ,; Sites in the 
US will enroll approximately 33% of total subjects. Each site will enroll a maximum of 60 subjects.  
Informed Consent 
Eligibility assessment  
(Day -28)
Run-In SOC period 
(- 28+10 days from visit 1)
Migraine Characteristics DiaryDiscontinueNot Eligable
EligableVisit 1
Eligibility Assessment
(Day 0)DiscontinueNot eligable
Subject enrolled 
1:1 Randomization
Device and PRO trainingEligable
Sham Self Practice 
Up to 2 self practice sessions
(up to day 14)Active Self Practice 
Up to 2 self practice sessions
(up to day 14)
Device logs and PRO 
verification
(Remote)
(up to day 14) Discontinue
 1. 60Â±[ADDRESS_351426] treatment
(Up to 5 Migraine epi[INVESTIGATOR_288312] 70)Visit 2
Visit 3
Visit 4Fail Fail
Pass PassDevice logs and PRO 
verification
(Remote)
(up to day 14) Discontinue
 1. 60Â±[ADDRESS_351427] treatment
(Up to 5 Migraine epi[INVESTIGATOR_288335] 70)
End of Study
Device return
(Up to 5 Migraine epi[INVESTIGATOR_288335] 70)End of Study
Device return
(Up to 5 Migraine epi[INVESTIGATOR_288335] 70)
 
Figure 3: Study Flowchart  
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351428]  provides informed consent, completes  the Run-in Period  and all required screening  and 
baseline procedures, and satisfies  the study  eligibility  criteria .  
6.3. Measures to Minimize Bias  
Several measures will be implemented to minimize systematic error/bias:  
â€¢ Randomization to active treatment vs. sham control.  
â€¢ Blinding of both subjects and study personnel.   
â€¢ At the end of Visit 2, before starting the self -practice, subjects will be asked for their opi[INVESTIGATOR_288336].  Their response will be documented in the CRF.  
â€¢ Screening log will be completed by [CONTACT_288365].  The log will include reasons for exclusion  from the study.  
â€¢ Pain assessment will be performed using a subject diary .    
â€¢ Investigatorâ€™s reported serious adverse events and device related adverse events will be reviewed and 
adjudicated , if required,  by [CONTACT_288366] â€™s medical advisor for 
further review  and assessment .  The adjudicated results will be updated in the study CRF and used in 
all cases for purposes of data analysis.  
â€¢ Medical  monitoring will take place in reviewing safety data and ensuring appropriate repor ting of 
adverse events.  The sponsor , the Medical advisor  and Principal Investigator  [INVESTIGATOR_288337].  
â€¢ Clinical monitor s will verify patientsâ€™ data and ensure compliance with good clinical practice (GCP), 
CIP and other study req uirements.  
7. Selection of Subjects  
7.1. Study Population  
The study will include male and female subjects, [ADDRESS_351429] will sign a written informed consent form (ICF) 
that has been approved by [CONTACT_132580]/ E C of the respective clinical site or the 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 21 of 41 
 
Neurolief  Confidential  
  
  
central IRB/EC, during the screening visit . Written, informed  consent will be obtained for all patients 
who are potential study candidates prior to applying any study specific assessment to the subject or any 
data c ollection .  See Section 9.[ADDRESS_351430] informed consent procedure.  
Refer to Figure 1  for a summary of the study schedule of assessment.  Specifically, subjects will be 
evaluated at Visit 1 to assess whether they meet study eligibility criteria.   Those meeting all of the 
inclusion and none of the exclusion criteria will initiate the Run -In Period for 28 days (+10 days).  
Subjects will return for Visit 2 (Day 0) for a repeat assessment of eligibility.  Those found eligible will be 
enrolled and ran domized .  A subject is considered enrolled in the study when it is determined that all 
inclusion/exclusion criteria are met during visit 2 and after run -in period diary is assessed.  At this point 
they will undergo device, device app and Patient Reported O utcome (PRO) training  and will be asked to 
complete the blinding assessment .  Subjects will be sent home with the device and the study dedicated 
smartphone for a 2 weeks Self -Practice Period.  During these 2 weeks they will perform 2 self -training 
treatmen t sessions, not during a Migraine attack and complete the PRO. Device logs will be verified by 
[CONTACT_288367] 3 (potentially remote verification).  Subjects with at least [ADDRESS_351431] 1 and up to 5 migraine epi[INVESTIGATOR_1841], within up to 70 +[ADDRESS_351432].  Once completing the Treatment Period, they will return for end of study visit (Visit 4) during which 
the device will be returned, final data will be collected and the subjects will be exited from the study.  
Subjects found ineligible by [CONTACT_288368] 'screen failure' on 
the screening & enrollment log and will not ta ke part in the study.  Screen failure subjects will not be 
included in the intention -to-treat analysis, nor will they be counted as part of the target subject sample 
number .   
7.3. Inclusion Criteria  
In order to be included in the RIME study  patients must  fulfill all of the inclusion criteria.  
1. Subjects [ADDRESS_351433] meets the ICHD -3 (2018) diagnostic criteria for Migraine  with or without aura.   
3. Subject reports 1-6 Migraine attacks per month; other headaches no more than [ADDRESS_351434] having received supraorbital or occipi[INVESTIGATOR_288338] . 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351435] 6 months  of chronic migraine, New Daily Persistent Headache, and chronic tension -type 
headache  per ICHD -3 (2018) diagnostic criteria . 
4. Subject has >10 headache days per month  
5. Current medication overuse headache . 
6. Use of opi[INVESTIGATOR_288319] 1 month . 
7. Use of barbiturates in the prior 1 month . 
8. Implanted metal/shrapnel or electrical devices in the head (not including dental implants), a cardiac 
pacemaker or an implanted or wearable defibrillator.  
9. Received parenteral infusions for migraine within the previous [ADDRESS_351436] with implanted neurostimulators, surgical clips (above the shoulder line) or any medical 
pumps.  
13. Current drug abuse or alcoholism.  
14. Subject is participating in any o ther clinical study . 
15. Skin lesion or inflammation at the region of the stimulating electrodes.  
16. Personality or somatoform disorder.  
17. Pregnancy or Lactation.  
18. Women  with child bearing potential without medically acceptable method of contraception (NOTE: 
Females  of child bearing potential must have a negative pregnancy test) . 
19. Documented history of cerebrovascular event.  
20. Subject with recent brain or facial trauma (occurred less than 3 months prior to this study).  
21. Subject participated in a previous study with the R elivion device.  
22. The subject does not have the basic cognitive and motor skills needed to operate a smartphone.  
23. Subject with head circumference smaller than [ADDRESS_351437] with other significant pain problem that in the opi[INVESTIGATOR_288339].  
8. Study Procedures  
8.1. Schedule of Events  
The schedule of events is depi[INVESTIGATOR_28071] 1  and Figure 1 .   
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 23 of 41 
 
Neurolief  Confidential  
  
  
Table 1: Schedule of Events  
Visit  Visit 1  Run-In Period  Visit 2  Self-
Practice 
Period  Visit 3  Treatment 
Period  Visit 4  
Event / Timeline  Day -28 -28 +10 days from 
Visit 1  Day 0  up to Day 
14 remote; 
Up to Day 
14 Up to 5 
epi[INVESTIGATOR_1841] / 
Day 70 +10 Up to 5 
epi[INVESTIGATOR_1841] / 
Day 70 +10 
Written Informed Consent  X       
Eligibility assessment  X  X     
 
3-month migraine retrospective 
history  questionnaire   
 X  
     
Medical history & Demography  X       
Prophylactic anti -migraine & 
rescue headache medication  X  X1    X1 
Physical examination2 & Vital signs  X       
Documented significant change in 
health status ( e.g., surgery, 
accident, MI)   
X     
Pregnancy test3 X  X     
Run-in Diary   X      
Enrollment & Randomization    X     
Device and PRO4 training    X     
Device and PRO Self-practice    X X    
Blinding assessment  questionnaire    X     
Device logs and PRO verification    X5  X  X 
Active / sham treatment       X  
Diary PRO at baseline, 1, 2 & [ADDRESS_351438]  
questionnaire        X 
Adverse events    X    X 
End of study        X 
1 Document change in medications  
2 Physical exam to include: Head, eyes, ears, nose, throat (HEENT) , Lungs , Heart  and Neurologic exam ; Vital signs include blood 
pressure, pulse  and respi[INVESTIGATOR_697]  
[ADDRESS_351439] for women of childbearing potential only  
4 PRO: Patient Reported Outcome  
5 Device logs only at Visit 2   
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 24 of 41 
 
Neurolief  Confidential  
  
  
8.1.1.  Visit 1  - Run-in (day -28)  
Written below are the assessments to be completed at Visit 1:   
â€¢ Written informed consent .  
â€¢ Eligibility assessment . 
â€¢ 3-month migraine retrospective history  questionnaire .  
â€¢ Prophylactic anti -migraine & rescue headache medication  (all medications, preventive, prescribed 
acute, and over the counter are to be recorded) . 
â€¢ Medical history  & Dem ography . 
â€¢ Physical exam , including  Head, eyes, ears, nose, throat (HEENT), Lungs, Heart , Neurologic exam and 
Vital signs including blood pressure, pulse  and respi[INVESTIGATOR_697] . 
â€¢ Pregnancy test (for women of childbearing potential) . 
â€¢ Run-in Period diary dispensing and training .  
The research coordinator will review the study  requirements with the subject  to help ensure 
compliance.  Telephone numbers must be obtained from the subject  to ensure t he ability to contact 
[CONTACT_12552]/her.  
8.1.2.  Run-In Per iod (Day 0 -28+10 days)  
â€¢ Completion of the Run-In Diary by [CONTACT_288369] -in period .  A Subject who failed to 
complete the required information on the Run-In Diary  will be considered a screen failure . The diary 
will capture information with resp ect to frequency, intensity and duration of migraine epi[INVESTIGATOR_1841], 
existence of aura and other symptoms, use of rescue medications, and other types of headaches.   
Two ( 2) different Migraine epi[INVESTIGATOR_288340], at minimum, by 48 hours free of pain in 
between.  
â€¢ Study team may contact [CONTACT_132592]/her to fill in the diary  
8.1.3.  Visit 2  - Randomization  (28+10 days from Visit 1)  
Written below are the assessments to be completed at Visit 2:  
â€¢ Review of Run-in Diary.  
â€¢ Change in prophylactic anti -migraine & rescue headache medication  will be documented.  
â€¢ Documented significant change in health status ( e.g., surgery, accident, MI)  
â€¢ Pregn ancy test (women of childbearing potential only) . 
â€¢ Verification of eligibility . 
â€¢ Randomization to Group A (Active Treatment) and Group B (Sham Control) . 
â€¢ Subject will read the User manual and watch the  instructional video and be trained on the device by 
[CONTACT_3476] . 
â€¢ Device size will be adjusted to subject head circumferences . 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 25 of 41 
 
Neurolief  Confidential  
  
  
â€¢ Subject will self-practice  the device along with the mobile application  to become familiar with its use 
and with the stimulation.  
â€¢ Blinding Assessment  questionnaire.  
â€¢ Subject will be trained on the Patient Reported Outcome ( electronic/hard copy)  diary  for 
documenting the outcome measures and rescue medication intake.  
â€¢ Mobile application /Device logs  verification  for stimulation intensity . Stimulation intensity to be 
above  2mA . In case subject fail to reach a minimum stimulation intensity of 2mA , subject will be 
withdrawn.  
â€¢ Subject will be provided with the device, a dedicated smartphone , a subject â€™s instruction form  and 
Patient Reported Outcome  diary (electronic/hard copy ) for up to 14 days Self -Practice period at 
their home.  
â€¢ Adverse events occurring during the visit will be documented.  
8.1.4.  Self-Practice Period (up to 14  days)  
â€¢ Subjectâ€™s s elf-practice of the device and Patient Reported Outcome diary twice, not during a migraine 
epi[INVESTIGATOR_1865], for 30 -60 minutes.  Device Logs will be automatically uploaded by [CONTACT_288370] -based database.  
â€¢ Study team may contact [CONTACT_132592]/her to perform self-practice  
procedure . 
â€¢ Subject will notify study team once completing 2 self -practice sessions.  
8.1.5.  Visit 3  (remotely or clinic visit; up to day 14)  
Written below are the assessments to be completed at Visit 3:  
â€¢ A visit is needed in case device logs were not download to the study cloud -based data base , 
otherwise a remote contact [INVESTIGATOR_159369].  
â€¢ Upon subject notification of the completeness of 2 self -practice sessions : 
â€ Study team will confirm within device logs that the subject completed at least one self -practice 
session successfully.  Device logs shal l present Subjectâ€™s study code, Device serial number, Date 
of stimulation session, stimulation session timeline bar presenting stimulation events such as 
"pass", "fail", Device failure events. A stimulation session marked as â€œPassâ€ if a minimal 
stimulation  of 2 mA was delivered, or â€œFailâ€ if a minimal stimulation of [ADDRESS_351440] 30  minutes of a â€œPassâ€ session in the device log.  
â€ Study  team will verify correct reporting on PRO  and inform/ret rain subject on correct PRO 
reporting, if required . 
â€ If at least one self -practice session completed successfully, study team will contact  [CONTACT_288371]/her to use the device during up to 5 migraine epi[INVESTIGATOR_288341] 70 +10 
from Visit 2.  
â€ Call will be document ed and will be considered as remote study Visit 3.   
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 26 of 41 
 
Neurolief  Confidential  
  
  
â€ If both self -practice sessions are non-eligible , subject will be withdrawn from the study.   Study 
team will call the subject and invite him/her  to a study termination visit.  Subject invitation  will 
be considered as remote study Visit 3 , termination visit will be documented.  
8.1.6.  Treatment period (up to 5 treated Migraine epi[INVESTIGATOR_288312] 70 +[ADDRESS_351441])  
â€¢ Subjects will use the device for at least 1 and up to 5 migraine epi[INVESTIGATOR_288341] 70 +[ADDRESS_351442].  
â€¢ Subjects will be instructed to differentiate between 2 different Migraine epi[INVESTIGATOR_288342], at minimum, 48 hours free of pain in between.  
â€¢ Study team will c ontact the subject periodically to remind him/her to use the device during his/her 
next migraine epi[INVESTIGATOR_1865].  
â€¢ Study team will periodically verify device logs of treated attacks on the study cloud database and  
may contact [CONTACT_132595] -training if required.  
â€¢ Subject will use the device a t home or surroundings immediately upon  the initiation  of the Migraine 
headache  and no later than 30 minutes after wards : 
â€ Subject will initiate the treatment procedure by [CONTACT_288372]. The mobile application will guide the subject through the treatment procedure 
steps and will direct him/her to the study Patient Reported Outcome diary when required.  
â€ Prior to initiating the treatment, subject will report on the Patient Reported Outcome diary that : 
â–ª He/she did not use analgesics or other pain relief drugs  or cannabis within 4 hours period 
before the treatment . 
â–ª Confirm n o more than [ADDRESS_351443] passed since Migraine  epi[INVESTIGATOR_288343] .  
â–ª Confirm t hat at least [ADDRESS_351444]  previous Migraine 
epi[INVESTIGATOR_1865] . 
â–ª Confirm he/she did not wake up with a Migraine headache . 
In case subject used a nalgesics or other pain relief drugs  or cannabis  within 4 hours period 
before the treatment initiation and/or more than 30 minutes passed from the start of the 
migraine epi[INVESTIGATOR_288344]/or less than [ADDRESS_351445]â€™s previous 
Migraine epi[INVESTIGATOR_288344]/or subject woke up with a Migraine  headache , subject will be 
instructed to refrain from using the device and await his/her next migraine epi[INVESTIGATOR_1865].  
â€ Prior to initiation of treatment  and no later than [ADDRESS_351446] will document on the Patient Reported Outcome diary  his/her baseline 
migraine pain level (whereas 1=Mild pain, 2=Moderate pain, 3=Severe pain)  and the most 
bothersome migraine -associated symptom (nausea, photophobia , phonopho bia or none).  
â€ Subject will then initiate the treatment  along with the dedicated mobile application . The 
treatment will last 60 Â±30 minutes. The Relivion â„¢ device programmed treatment duration will be 
[ADDRESS_351447] may stop treatment earlier  
but not less than 30 minutes from treatment start.  If necessary, treatment can be paused by [CONTACT_288373]: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351448] 30 minutes of a 
"pass"  session  on the device log timeline, will count as a completed treatment.  
â€ Subjects will be asked to refrain from consuming rescue medication /cannabis  for at least [ADDRESS_351449] treatment initiation.  Subjects using rescue medication /cannabis prior to [ADDRESS_351450] 
treatment initiation will be considered as failure (will be assigned the value of 0=no headache 
pain reduction) in the primary analysis.  
â€ Subjects will document on the Patient Reported Outcome diary:  
â–ª Pain according to a 4 points scale  (0=no pain, 1=Mild pain, 2=Moderate pain, 3=Severe pain)  
at 1 and 2 hours Â±30 minutes and at 24 hours Â±[ADDRESS_351451] initiation of treatment.   
â–ª Most Bothersome migraine -associated Symptom (MBS) other than a headache  (chosen at 
baseline) improvement (yes/no ) at 1 and 2 hours Â±[ADDRESS_351452] -treatment initiation . 
â–ª Rescue medication intake.  
8.1.7.  Visit 4 - Termination visit  (following 5 treated Migraine epi[INVESTIGATOR_288345] 70 +10, whichever comes first)  
Written below are the assessments to be completed at Visit 4:  
â€¢ After up to 5 migraine epi[INVESTIGATOR_288341] 70 +10, whichever comes first, subject will report to 
the clinic and return the device , Smartphone  and hard copy subject diary, if applicable .  
â€¢ Change in prophylactic anti -migraine & rescue headache medicatio n will be documented.   
â€¢ Subjects device Global Impression of Effect  will be documented.  
â€¢ Adverse events will be documented .  
â€¢ Device logs , for each Migraine treated epi[INVESTIGATOR_1865], will be downloaded by [CONTACT_3476] (from study 
cloud database or from the device) t o ascertain eligible treatments .  An eligible treatment is defined 
as: 
â€ treatment  meeting the basic criteria ( i.e., no analgesics or other pain relief drugs or cannabis 
within 4 hours period before the treatment initiation; no more than 30 minutes passed fr om the 
start of the migraine epi[INVESTIGATOR_1865]; more than [ADDRESS_351453]â€™s previous 
Migraine epi[INVESTIGATOR_1865] ; and subject did not wake up with a Migraine headache); and   
â€ with total stimulation time of at least 30 minutes of a "pass"  session  on the device log timeline , 
where pass is defined as a minimal stimulation of 2mA delivered).    
The characteristics of each treatment will be indicated on the subject CRF.  
At this point  subjectâ€™s participation in this study will be over. The subjects will continue receiving 
medical care as per local standard of care, but not within the clinical study. Adverse Events that are still 
ongoing will be followed per local standard of care, but not within the clinical study.  
8.2. Prior and Concomitant Medications  
During the Run -In and Self -Practice Periods, the subject will use prophylactic medications as prescribed 
and rescue medications as needed and will document their use in the Migraine Diary.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN [ADDRESS_351454] will continue his/her prophylactic medications  and rescue 
medications as needed .  While using the Relivionâ„¢ the subject will be asked to refrain from taking 
rescue medications /cannabis  in the [ADDRESS_351455] Consent  
Informed consent will be obtained before any study -specific procedures are initiated or data collected. 
Principal Investigator [INVESTIGATOR_022]/her authorized designee will conduct the informed consent process.  
8.4. Rando mization , Treatment Assignment  and Blinding  
Subjects  will be prospectively  randomized into  the clinical  study.   Randomization will  occur  only  after  
the subject  provides informed consent, completes  the Run -in Period and all required screening  and 
baseline procedures, and satisfies  the study  eligibility  criteria . Eligible subjects will be randomly 
allocated (with a 1:1 ratio) to one of the following 2 treatment groups based on a randomization scheme 
using the permuted block method stratified by [CONTACT_384]:  
â€¢ Group A - active stimulation.  
â€¢ Group B - sham stimulation.  
The randomization scheme will be prepared by [CONTACT_288374] (version 9.4.) random 
number procedure. The block size will be random, and all study personnel will therefore be blinded to 
the randomization block size.  Only  the unblinded  statistician  /sponsor unblinding party  and designates  
will be privy  to the masked  randomization  scheme.  
The Relivionâ„¢ Active and Sham devices will look the same and will be provided in the same packaging 
bearing the same labeling.  Hence, both subjects and study personnel will remain blinded to the 
assigned treatment group.    
8.5. Medication Compliance  
While using the Relivionâ„¢ the subject will be asked to refrain from taking rescue medications/cannabis 
in the [ADDRESS_351456] will ascertain he/she did not 
consume any rescue medications/cannabis in the 4 hours prior to study treatment initiation. During 
each study treatment and up to 24 hours afterwards subjects will document any rescue 
medication/cannabis intake. PRO data of s ubjects who consume d rescue medications/can nabis will not 
be considered  for the analysis of the related treatment time point .  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 29 of 41 
 
Neurolief  Confidential  
  
  
8.6. Assessment of Efficacy  
Efficacy parameters including Pain level, use of rescue medications /cannabis , presence and r elief of 
most bothersome migraine -associated symptom  othe r than headache  will be documented during 
treatment at baseline, [ADDRESS_351457] using the diary  (electronic or hard copy) . 
Treatment duration and intensity will be documented automatically i n the device logs.  
8.7. Assessment of Safety  
Safety will be assessed by [CONTACT_288375] (randomization) 
through study exit. Type, incidence, severity, duration, and procedure/device relationship of adverse 
events (AE s) will be collected throughout the study. Subjects with AEs at study exit  will be followed for 
[ADDRESS_351458]. Adverse event data will be collected and reported 
on eCRFs.  
9. Risks and Benefits  
Risk management is performed as per ISO [ZIP_CODE], complete documentation is maintained on file  
(Neurolief document #  QAD -022).  
9.1. Risk Control and Mitigation  
The following efforts will minimize risks to subjects in the study:  
â€¢ Conduct of the study following successful completion of extensive bench performance testing and 
careful risk analysis.  
â€¢ Selecti on of investigators who are experienced and skilled in management of patients with migraine.  
â€¢ Establishment of a training program for study staff members (investigators and coordinator) and use 
of tools that will ensure proper training to the subjects for h ome use of the device.  
â€¢ Clearly defining the inclusion and exclusion criteria such that only appropriate patients are enrolled 
in the study.  
9.2. Risk-Benefit Rationale  
Assessing the risks against the potential benefits of the use of the Relivionâ„¢  for alleviatin g migraine 
pain , Neurolief  and the principal investigator s have determined that there is a high likelihood that the 
expected benefit may outweigh the risk in patients fulfilling the study eligibility criteria.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 30 of 41 
 
Neurolief  Confidential  
  
  
10. Adverse Event s and Device Deficiencies  
Adverse  event definitions used in this study are based on ISO [ZIP_CODE]:2011 (Clinical Investigation of 
Medical Devices for Human Subjects -- Good Clinical Practice ).  
Adverse Events will be collected for all enrolled subjects with the point  of enrolment  (Visit #2) and end 
at the study termination visit (visit #4) . Subjects with AEs at termination visit  will be followed for [ADDRESS_351459].  
During the course of the study, all AEs will be collected and reported on the  eCRF  including :  
â€¢ All AEs related to Relivion device and/or procedure   
â€¢ All AEs not related  to Relivion device and/or procedure  
â€¢ All device deficiencies that may lead to a SAE  
â€¢ All Deaths  
10.1.  Relivion Anticipated Adverse Events  
Possible risks and adverse events that may be associated with the Relivionâ„¢ device are based on  
adverse events reports of similarity devices include, but are not limited to the following:  
â€¢ Unpleasant sensation during treatment  
â€¢ Scalp Numbness sensation during and after treatment  
â€¢ Pers istent tingling sensation after the treatment ends  
â€¢ Pain  
â€¢ Skin reaction (for example, irritation, lesion, burn) beneath the stimulation electrodes  In this case, 
treatment should be temporarily discontinued.  
â€¢ Redness of the skin under or around the electrodes.  Skin redness usually disappears within several 
hours after treatment  
â€¢ Sleepi[INVESTIGATOR_008], fatigue or sleep disorders  
â€¢ Sedative effect during or after treatment  
â€¢ Dizziness during or after treatment  
â€¢ Tension type headache after treatment  
10.1.1.  Reporting of Adverse Events  
Please refer to Table [ADDRESS_351460] of the minimum AE reporting requirements for Investigators. If local 
regulations or IRB/EC require faster reporting, then the Investigator will adhere to those requirements. 
Reporting of all safety events to the S ponsor will be completed through Investigator submission of the 
AE eCRF in the remote data capture (RDC) system. In case of emergency only for SAEs (ex. RDC system is 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 31 of 41 
 
Neurolief  Confidential  
  
  
unavailable), the sponsor site representative  may be contact[CONTACT_43417]; this will not se rve as a 
substitute for proper reporting on the appropriate eCRF.  
Table 2: AE Reporting Requirements  
Type  Report to  Reporting Timeframe (from time of 
learning of event)  
Adverse Event (AE)  Sponsor  Within 10 working days  
IRB/ EC Per EC reporting requirements  
Serious Adverse Event (SAE)  Sponsor  Within 24 hours  
IRB/ EC Per/IRB/  EC reporting requirements  
Adverse Device Effect (ADE), Serious 
Adverse Device Effect (SADE) and 
Unanticipated Serious Adverse Device 
Effect ([LOCATION_003]DE /UADE ) 
 Sponsor  Within 24 hours  
IRB/ EC Per EC reporting requirements  
 
Device Deficiency  Sponsor  Within 48 hours   
IRB/ EC If SAE occurs due to the device 
deficiency, within 24 hours of 
learning of the event and per EC 
reporting requirements  
EC Per EC reporting requirements  
 
Events will be reviewed by [CONTACT_132622]/EC. Reporting will occur within the timelines per local regulations and 
requirements.  The Principle Investigator is responsible to report the events to the IRB/ EC. 
The sponsor shall immediately conduct an evaluation of any unanticipated events if determines that the 
events presents an unreasonable risk to subje cts, report the results of such evaluation to the Regulatory 
authority  and to reviewing IRB/ EC and participating investigators within [ADDRESS_351461] supplemental information if needed. 
For SAE, U (SA)DE and ADE (as classified by [CONTACT_093]) a narrative will be prepared and adjudicated 
for assessing  the relatedness, seriousness and possible action items required.  The sponsor  may ask for 
further information or clarif ication from the investigator. A  summary of the adjudication results  will be 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 32 of 41 
 
Neurolief  Confidential  
  
  
issued ; if different than investigatorâ€™s report, PI [INVESTIGATOR_288346].  
Adjudicated events will serve as a basis for reporting AE/SAE.  Differences between site -reported events 
and adjudicated events  will also be presented and discussed in the report.  
11. Statisti cal Considerations  
11.1.  Study Endpoint Variables  
11.1.1.  Primary endpoint variable  
The primary endpoint, the proportion of subjects reporting reduction of migraine headache pain [ADDRESS_351462] treated migraine attack, when using active combined occipi[INVESTIGATOR_288347], in subjects suffering from acute migraine headache, 
will be measured in the form of a binary variable which will be assigned the value of â€œ1â€ if the subject 
reports such headache pain reduction without having used rescue medications, and â€œ0â€ otherwise. 
Rescue medication use within the [ADDRESS_351463] will be 
coded as â€œ0â€ automatically.   
11.1.2.  Secondary endpoint variables  
The three secondary endpoints will also be represented in the form of binary variables which will be 
assigned the value of â€œ1â€ if the subject is a â€œresponderâ€ to each specific secondary endpoint, and â€œ0â€ 
otherwise.  
11.1.3.  Exploratory endpoint variables  
The exploratory endpoints will be measured in the form of a binary variables which will be assigned the 
value of â€œ1â€ if the subject responds to each specific exploratory endpoint, and â€œ0â€ otherwise.  
Global Impression of Effect will also be measured via a 5 -level Likert scale.  
11.1.4.  Safety endpoint variables  
Incidence of all adverse events and complications by [CONTACT_132628].  
11.2.   Study Hypothesis  
Study Hypothesis:  
H0: PT = P S 
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 33 of 41 
 
Neurolief  Confidential  
  
  
HA: PT â‰  PS 
Where PT and PS represent the proportions (%) of subjects  reporting pain relief in the active treatment 
group and sham group respectively.  
11.3.  Sample Size Estimation  
The sample size for this study was calculated to test the null hypothesis with a chi -squared test, even 
though the final analysis may employ a regressi on model and/or a Fisherâ€™s exact test.  
The sample size is calculated to test the null hypothesis with 80% power at a 5% level of significance  
using the POWER procedure in SAS v9.4 .  
If we assume that 45% of the subjects in the active treatment arm will ha ve successful pain relief versus 
25% in the sham arm then 180 evaluable subjects are required, 90 per group. Allowing for a ~10% drop -
out rate, a total of 200 (100 active vs. 100 sham) subjects should be enrolled in the study.      
11.4.  Interim Analysis  
Planning  one interim analysis that permits an increase in the sample size as described below does not 
additionally inflate the type I error [ 22-24]. In addition, the final analysis is performed using the 
conventional test as appropriate for the statistical hypothe sis. 
One interim analysis is planned once ~ 80% of the information is collected, i.e. the interim look will be 
performed after [ADDRESS_351464] been accrued. Based on the conditional power at the 
interim analysis, the study will either continue to the originally planned sample size if the result is 
â€œfavorableâ€, stop for futility if the result is â€œunfavorableâ€, or we shall increase the sample size if the 
result is â€œpromisingâ€. These decisions will be made based on the conditional power (CP), defined as the 
conditional probability that the final result will exceed a critical value at the interim given the observed 
effect size ð›¿1 = difference between pain reductio n rates in the active versus control groups at the 
interim look. The following guidelines for sample size increase, depending on the zone into which CP 
falls at the interim, the calculated CPmin, the maximum sample size designated of 340 for the study and 
the % of the originally planned sample size at which the interim analysis will be performed. Following 
this principle does not inflate the Type I error.  
The sponsor and the clinics will remain blinded throughout the study to the interim analysis results as  
well, only the decision made will be shared.  
Notation : 
n1= sample size at interim analysis  
n2= sample size calculated based of effect size obtained at interim  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 34 of 41 
 
Neurolief  Confidential  
  
  
nmax = the highest sample size the company is willing to use/ can afford, n max = [ADDRESS_351465] size of 15% in the same manner as above in Section 12.3 .  
CPmin=is the calculated minimum CP based on the ratios n max/n2, n1/n2 and the target study power 
(80%).  
11.4.1.  Procedure  
After all the relevant data will be entered into the database, and the database cleaned, a soft lock to the 
database will be performed. An independent un -blinded statistician (not the study statistician)  will 
perform the assessments described below. A designated data monitoring team  will recommend whether 
to stop the study once the interim results are available.  
At the interim analysis, the data of the evaluable subjects  per ITT and m ITT will be analyzed . 
11.4.2.  Blinding  
Only  the unblinded statistician and members of the interim decision team  will be exposed to the interim 
report. The members of the  data monitoring team  may also have access to the unmasked information of 
the interim analysis. Investigators and company directors will only be informed of a decision to continue 
or to discontinue the trial, or to implement modifications in trial procedure. The un -blinded sta tistician 
who is responsible for conducting the interim analyses should ensure that the unmasked data is not 
available to any unauthorized person within or outside the company . 
11.4.3.  Decision Rules  
The following are the decision rules for the interim analysis wh ich will be performed upon accrual of 
80% of the sample size, 144 evaluable subjects:  
â€¢ If the result is â€œUnfavorableâ€, i.e. CP < CPmin = 32.91 % (interim result is so disappointing that it is 
not worth increasing the sample size to retrieve conditional power ) or if the difference between 
percentage of subjects reporting pain relief at the interim (Pt -Pc) is less than 0%, then stop the trial 
for futility.  
â€¢ If the result is â€œPromisingâ€, i.e. 32.91 % â‰¤ CP < 80% the sample size is increased recover the targeted 
pow er of 80%. The sample size used will be either the new calculated sample size based on the 
conditional power (as described in Sample size re calculation using conditional power Jonathan S. 
Denne Statist. Med. 2001; 20:2645 â€“2660) or the predetermined maximu m sample size of 340 
subjects.  
â€¢ If the result is â€œFavorableâ€, i.e. CP â‰¥ 80%  the interim results are sufficiently favorable and trial 
continues to the original sample size planned 180 without the need to adaptively increase the 
sample size.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 35 of 41 
 
Neurolief  Confidential  
  
  
Note that the in terim analysis will be conducted on all population ( ITT, mITT  and PP  analysis sets , see 
Section 12.6 ), and the study will be stopped due to futility only if the interim effects in both populations 
fall below the threshold . 
11.4.4.  Controlling the Alpha Level for t he Primary Endpoint  
The overall alpha level for this study is 5%. According to [ references 1-2-3], planning an interim analysis 
that permits an increase in the sample size as described above does not inflate the type I error.  
11.5.  Randomization   
Upon completion  of the run -in period, eligible subjects will be randomly allocated (with a 1:1 ratio) to 
one of the following 2 treatment groups based on a randomization scheme using the permuted block 
method stratified by [CONTACT_384]:  
â€¢ Group A â€“ active  (Relivion â„¢) stimulation  
â€¢ Group B = sham stimulation  
The randomization scheme will be prepared by [CONTACT_132534] (version 9.4.) random 
number procedure. The block size will be random, and all study personnel will be therefore blinded to 
the random ization block size.  
11.6.  Analysis Populations  
Intent -to-Treat (ITT) Population : The ITT population will include all randomized subjects, according to 
the ITT principle all subjects will be kept in a group as randomized.  
Modified Intent -to-Treat (mITT) Population : The mITT population will include all randomized subjects 
who treat at least one eligible attack (excluding the " self-practice  test"), with group assignment as 
treated.  
Per-Protocol Population : The Per -Protocol population will include all subjec ts in the mITT population 
who completed the treatment period in compliance with the protocol and have no major protocol 
deviations, with group assignment as treated.  
The ITT analysis set will serve as the main analysis set for all safety evaluations.  
The e fficacy analyses will be performed on the mITT analysis set.  
The primary and secondary efficacy assessments will also be performed on the PP and the ITT analysis 
sets as a sensitivity analysis.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 36 of 41 
 
Neurolief  Confidential  
  
  
11.7.  Statistical Analysis  
11.7.1.  General  Considerations  
Statistical analy ses will be performed using SASÂ® v9.4 (SAS Institute, Cary NC, [LOCATION_003]). Statistical analyses 
and reporting will be performed in compliance with FDA Guidance E6 GCP, 21 CFR part 812, E9 and ISO 
[ZIP_CODE].  
All statistical tests will be two -sided. The required signi ficance level of findings will be equal to or lower 
than 5%, nominal p -values will be presented. Where confidence limits are appropriate, the confidence 
level will be 95%.  
Continuous variables will be summarized by a mean, standard deviation, minimum, medi an and 
maximum and categorical variables by a count and percentage. For comparison of means (continuous 
variables), the two -sample t -test or the Wilcoxon rank sum test will be used as appropriate. For 
comparison of proportions (categorical variables), the chi-squared test or Fisherâ€™s exact test will be used 
as appropriate.  
If multiple measurements are taken in a single patient, statistics described below will be appropriately 
modified to accommodate the within patient correlation.  
Deviations from the planne d analysis will be described, with proper justification, in the clinical study 
report.  
11.7.2.  Significance Level and Handling of Type I Error  
Type I Error  
The overall significance level for this study is 5% using two -tailed tests, except for treatment by [CONTACT_132631] a significance level of 10%.  
Hierarchy Approach for Secondary Endpoint Analysis   
The hierarchy approach will be adopted for the primary and secondary endpoints to control type I error 
due to multiple endpoint testing. Thus,  the primary endpoint will first be tested and only if p<0.05, will 
the secondary endpoints be tested. For the three secondary performance endpoints, the Benjamini â€“
Hochberg step -up method will be used to adjust the p -values.  
11.7.3.  Demographic and Other Baseline Characteristics  
Demographic and baseline condition related characteristics will be tabulated and compared between 
the study groups by [CONTACT_89714], this data will also be compared between US and OUS sites for poolability 
confirmation. Continuous variables wil l be summarized by a mean, standard deviation, minimum, 
median and maximum and categorical variables by a count and percentage.  
These data will include:  
â€¢ Demographic data  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 37 of 41 
 
Neurolief  Confidential  
  
  
â€¢ Medical history  
â€¢ Type of pain medications/treatments used for migraine as well as rescue  
â€¢ Other concomitant medication  
â€¢ Migraine attacks characteristics  
â€¢ Physical examination  
11.7.4.  Disposition of Subjects  
The number of subjects who entered the study and completed each stage of the study will be provided, 
as well as the reasons for all post randomization discontinuations, grouped by [CONTACT_57117], e.g., lost to 
follow -up, adverse event, poor compliance, did not administer any treatment (with reasons). A list of 
discontinued patients, protocol deviations and subjects excluded from the performan ce analysis will be 
provided as well.  
11.7.5.  Efficacy Analysis  
Primary Efficacy Analyses   
The primary endpoint is the proportion (%) of patients reporting reduction in their pain level [ADDRESS_351466] treated eligible (per Section 9.1.6 ) migraine attack (excluding the "self -practice" 
treatment).  A count and percentage of subjects reporting such headache pain reduction without rescue 
medications wi ll be calculated and presented for both study groups, each with a two -sided 95% exact 
confidence interval. The groups will be compared with a chi -squared test and a Fisherâ€™s exact test.  
If the null hypothesis is rejected in favor of the alternative hypoth esis and the proportion (%) of subjects 
responding to this endpoint in the active group is greater than that of the sham group, the study will be 
deemed successful.  
The primary endpoint will also be evaluated stratified by [CONTACT_288376] a Mantel -Haenszel te st to assess 
the center by [CONTACT_102938].  
A sensitivity analysis of the primary end -point will be performed to assess the impact of missing data on 
the study outcome. This will be performed using several possible imputation methods.  
Subset Analyses of Primary Endpoint  
Adjustment for other covariates such as demographics or other baseline patient characteristics may be 
performed by [CONTACT_288377] a logistic regression model.  
Subgroup analysis will be performed and reported by [CONTACT_288378] a logistic 
regression model:  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 38 of 41 
 
Neurolief  Confidential  
  
  
â€¢ use of migraine medications  
â€¢ blinding assessment  
â€¢ US vs. OUS sites  
Secondary Efficacy Analyses  
The secondary efficacy variables will be summarized by a count and percentage and compared with a 
chi-square d test and a Fisherâ€™s exact test.  
 
Exploratory Analyses  
The exploratory variables will be summarized by a count and percentage and compared with a chi -
squared test and a Fisherâ€™s exact test.  
Global Impression of Effect will also be summarized by [CONTACT_288379] a t -test.  
Frequency of use of rescue medications will be summarized by [CONTACT_288380] a t -test.  
Safety Analysis  
The pri mary safety variable, the cumulative incidence (and 95% CI) of device related adverse events 
(AEs) throughout the study, will be presented in tabular format and will include incidence tables by 
[CONTACT_926].  
Adverse event rates will be compared between the stu dy groups with a Fisherâ€™s exact test.  
Serious adverse events will be listed and discussed individually.  
Treatment tolerability will be compared between the study groups. The number and percent of subjects 
who fail to complete the study and the number and percent of subjects who fail to complete the study 
because of Adverse Events will be presented as well.  
Handling of Missing Data  
Multiple imputation for binary data will be used as the primary imputation method in the case of 
missing data for the prim ary efficacy end -point.  
Additional sensitivity analysis of the primary end -point will be performed to assess the impact of missing 
data on the study outcome using possible imputation methods for binary data:  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 39 of 41 
 
Neurolief  Confidential  
  
  
Observed Data: Use only subjects with non -missin g pain data and who did not withdraw early from 
study  
Dropout/AE Imputation: A subject with no post baseline measurement of pain or a subject withdrawn 
due to an adverse event or treatment intolerability should be considered as a nonresponder for this 
analysis.  
Best Case Scenario: Assume all visits with missing pain data in active group are successes. Assume all 
subjects in the sham group with missing pain data are failures.  
Worst Case Scenario: Assume all visits with missing pain data in active group are failures. Assume all 
subjects in the sham group with missing data are successes.  
Imputation of missing data may be performed on secondary and exploratory endpoints as well.  
Pooling  
Subgroup analysis of the primary efficacy endpoint by [CONTACT_384], and US vs OU S, will be used to evaluate 
the poolability of the results. The significance of center -to-center variability in treatment effect will be 
evaluated by [CONTACT_288381] a logistic regression model. 
In the case tha t poolability is questionable, the reasons for differential treatment effect, such as subject 
and clinical characteristics, will be investigated and reported.  
  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 40 of 41 
 
Neurolief  Confidential  
  
  
12. References  
1. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American 
Migraine Study. Headache 1998 Feb;38(2):87 â€“96. 
2. See, World Health Organization, Headache Disorders, available at 
http://www.who.int/mediaacentre/factsheets/fs277/en/ .  
3. Lipton, R.B., et al., Migraine prevalence, disease burden, and the need for preventive therapy.  
Neurology, 2007. 68(5): p. 343 -9. 
4. Loder, E., Triptan therapy in migraine. New England Journal of Medicine , 2010. 363(1): p. 63 -70. 
5. Silberstein, S.D., et al., Safety and efficacy of peripheral nerve stimulation of the occipi[INVESTIGATOR_288348]: results from a randomized, multicenter, double -blinded, 
controlled study. Cephalalgia, 2012. 32(16): p. 1165 -79. 
6. Serra, G. and F. Marchioretto, Occipi[INVESTIGATOR_132518]: a randomized trial. 
Pain Physician, 2012. 15(3): p. 245 -53. 
7. Vadivelu, S., et al., Occipi[INVESTIGATOR_288349] m alformation  
population. Neurosurgery, 2012. 70(6): p. 1430 -6; discussion 1436 -7. 
8. Saper, J.R., et al., Occipi[INVESTIGATOR_132519]: ONSTIM feasibility study. Cephalalgia, 2011. 31(3): p. 271 -85. 
9. Paemeleire, K., et al., Phenotype of patients responsive to occipi[INVESTIGATOR_288350]. Cephalalgia, 2010. 30(6): p. 662 -673.  
10. Reed, K., et al. Combined occipi[INVESTIGATOR_132523]: an extended case series. in 15th Congress of the International Headache Society. 2011.  
11. Hann, S. and A. Sharan, Dual occipi[INVESTIGATOR_132524]: a 
singlecenter experience, review of literature, and surgical considerations. Neurosurg Focus, 2013. 
35(3): p. E9.  
12. Solomon, S. and K.M. Guglielmo, Treatment of headache by [CONTACT_288382].  
Headache, 1985. 25(1): p. 12 -5. 
13. Schoenen, J., et al., Migraine prevention with a supraorbital transcutaneou s stimulator: a 
randomized controlled trial. Neurology, 2013. 80(8): p. 697 -704.  
14. Magis, D., et al., Safety and patientsâ€™ satisfaction of transcutaneous Supraorbital NeuroStimulation  
(tSNS) with the CefalyÂ® device in headache treatment: a survey of 2,313 he adache sufferers in the  
general population. The journal of headache and pain, 2013. 14(1): p. 1 -8. 
15. Trigeminal Nerve Stimulation Provides Pain Relief in Epi[INVESTIGATOR_218975]. Presentation at  
the 18th Congress of the International Headache Society ( IHC) 2017. Presented September 9, 2017  
16. Schwedt, T.J., Occipi[INVESTIGATOR_132518] --interpreting the ONSTIM feasibility 
trial. Cephalalgia, 2011. 31(3): p. 262 -3. 
17. Ahmed, H.E., et al., Use of Percutaneous Electrical Nerve Stimulation (PE NS) in the Short term  
Management of Headache. Headache: The Journal of Head and Face Pain, 2000. 40(4): p. 311 -315.  
18. Tubbs, R.S., et al., Landmarks for the identification of the cutaneous nerves of the occiput and 
nuchal regions. Clinical Anatomy, 2007. 20( 3): p. 235 -238.  
19. Mueller, O., et al., Stimulation of the greater occipi[INVESTIGATOR_17719]: anatomical considerations and clinical  
implications. Pain Physician, 2013. 16(3): p. E181 -9 
20. Goadsby, P. J., Migraine Pathophysiology. Headache: The Journal of Head and Face Pa in, 2005. 45: 
S14â€“S24.  
 THE RIME STUDY: ABRIDGED 
CLINICAL INVESTIGATION PLAN   Doc No.:  CL-CIP-001 Abridged  
Ref Rev: REV. 2 / 11JUN 2019 
Pg. 41 of 41 
 
Neurolief  Confidential  
  
  
21. Hering, H.R, Efficacy and Safety of Combined Occipi[INVESTIGATOR_288351]: A Prospective, Randomized, Single -blind, 
Parallel -group, Placebo Controlled Clinical Study . Poster session presented at the 18th congress of 
the international headache society (IHC), Vancouver, Canada 2017.  
22. MÃ¼ller HH, SchÃ¤fer H., Adaptive group sequential designs for clinical trials: combining the 
advantages of adaptive and of classical group s equential approaches. Biometrics. 2001;57:[ADDRESS_351467]. Med. 2001; 20:2645 â€“
2660  
24. Broberg., Sample size re -assessment leading to a raised sample size does not inflate type I error ra te 
under mild conditions. Medical Research Methodology 2013, 13:94  
 
 
 
 
 
 
 